吉利德以8000万美元预付款从中国基石药业引进抗癌药物。
Gilead gets cancer drug from China-based Genhouse for $80M upfront
生物技术与制药领域的最新动态
Gilead gets cancer drug from China-based Genhouse for $80M upfront
Pentagon adds, then withdraws, WuXi AppTec to Chinese military list
Lilly appeals retatrutide classification ruling in case that could impact compounders
Epigenetic editing startup Moonwalk shifts focus to siRNA for obesity
Lundbeck migraine prevention drug succeeds in Phase 2, advancing new therapy class
Moderna's flu shot dilemma muddies 2028 break-even guidance
Lilly stockpiles $1.5B worth of weight loss pill ahead of US approval
Immunic's private placement; Vertex's cystic fibrosis data in young kids
Paul Hudson couldn’t quite get Sanofi over the hump; PROTAC developer Arvinas appoints CEO
PTC Therapeutics withdraws US filing for troubled Duchenne treatment Translarna
Ultragenyx to lay off about 130 employees after rough 2025
Icon's stock drops 40% after disclosing internal accounting probe
AbbVie sues over selection of Botox for IRA negotiations
Pharma pushes back on FDA plans to ease prescription-OTC drug switches
Novo Nordisk to expand Irish factory for Wegovy pill
Cassidy bill seeks to ban a customs loophole on pharma's radar
Sanofi’s new CEO Belén Garijo gets frosty reception as challenges await
A pancreatic cancer approval; Seres cuts staff
Even Europeans don't see a future in Euro biopharma anymore
Terray says its AI model beats Boltz-2 at binding affinity prediction